Output details

An automated microscale platform for evaluation and optimization of oxidative bioconversion processes.

The uptake of oxidative biocatalysts in pharmaceutical manufacture has been hindered by long development times. We demonstrate how, using automated microscale technologies, oxidative bioconversions can be designed with a reduced cost and timeframe compared to conventional experimentation. Substrate specificity and product selectivity were demonstrated with previously untested substrates and two novel products synthesized. Successful 90,000-fold scale-up provides confidence in the approach and extends the BiCE impact case study findings to oxidative bioconversions. This work led to new EngD project with Synthace (Dr Markus Gershater, CSO, m.gershater@synthace.com) and to a €10.5M EU-wide collaborations as part of the FP7 BIONEXGEN Project.